Journal of Diabetes Research

Journal of Diabetes Research / 2017 / Article

Review Article | Open Access

Volume 2017 |Article ID 5947859 | 13 pages | https://doi.org/10.1155/2017/5947859

Akt/mTOR Role in Human Foetoplacental Vascular Insulin Resistance in Diseases of Pregnancy

Academic Editor: Christian Wadsack
Received01 Jun 2017
Accepted15 Aug 2017
Published14 Sep 2017

Abstract

Insulin resistance is characteristic of pregnancies where the mother shows metabolic alterations, such as preeclampsia (PE) and gestational diabetes mellitus (GDM), or abnormal maternal conditions such as pregestational maternal obesity (PGMO). Insulin signalling includes activation of insulin receptor substrates 1 and 2 (IRS1/2) as well as Src homology 2 domain-containing transforming protein 1, leading to activation of 44 and 42 kDa mitogen-activated protein kinases and protein kinase B/Akt (Akt) signalling cascades in the human foetoplacental vasculature. PE, GDM, and PGMO are abnormal conditions coursing with reduced insulin signalling, but the possibility of the involvement of similar cell signalling mechanisms is not addressed. This review aimed to determine whether reduced insulin signalling in PE, GDM, and PGMO shares a common mechanism in the human foetoplacental vasculature. Insulin resistance in these pathological conditions results from reduced Akt activation mainly due to inhibition of IRS1/2, likely due to the increased activity of the mammalian target of rapamycin (mTOR) resulting from lower activity of adenosine monophosphate kinase. Thus, a defective signalling via Akt/mTOR in response to insulin is a central and common mechanism of insulin resistance in these diseases of pregnancy. In this review, we summarise the cell signalling mechanisms behind the insulin resistance state in PE, GDM, and PGMO focused in the Akt/mTOR signalling pathway in the human foetoplacental endothelium.

1. Introduction

Insulin modulates D-glucose homeostasis, and a reduced response or a lack of response to this hormone (hereafter referred as “insulin resistance”) is characteristic in several pathologies, including diabetes mellitus and obesity [1, 2]. Insulin resistance tightly relates with abnormal responses of the vascular endothelium, that is, endothelial dysfunction, to vasoactive molecules including insulin and the endogenous nucleoside adenosine [3, 4]. Human pregnancy courses with physiological maternal and foetal insulin resistance as an adaptive response to the increasing nutrient requirement by the pregnant women and the growing foetuses [5].

Insulin signalling involves preferential activation of the protein kinase B (PKB)/Akt (Akt) and mitogen-activated protein kinase (MAPK) signalling pathways [4, 6]. Vascular actions of insulin in the human placenta and umbilical cord vessels (hereafter referred as “foetoplacental vasculature”) are of relevance since this vascular bed lacks innervation, and the control of the blood flux results from local release of vasoactive molecules [4, 7]. The mechanisms behind vascular insulin effects include the synthesis of nitric oxide (NO) by the endothelial NO synthase (eNOS) isoform, ATP release, and adenosine-mediated increase of L-arginine transport and NO synthesis [4, 8, 9]. Pathologies of pregnancy, such as preeclampsia (PE) [10] and gestational diabetes mellitus (GDM) [4, 11], and abnormal maternal conditions, such as pregestational maternal obesity (PGMO) and maternal obesity in pregnancy [12], show with reduced insulin signalling in the foetoplacental vasculature. In this review, we propose that common signalling mechanisms result in insulin resistance of the human foetoplacental vasculature in these diseases.

2. Insulin Signalling

Insulin activates the splice variants A (IR-A) and B (IR-B) of insulin receptors (IRs) in the human foetoplacental vasculature [13]. IR-A and IR-B are expressed in this vascular bed with IR-A showing higher affinity for insulin than that with IR-B [4, 13, 14]. IR activation by β-subunit autophosphorylation recruits and phosphorylates two protein families, that is, the insulin receptor substrates (IRSs) and the Src homology 2 domain-containing transforming protein 1 (SHc) [15] (Figure 1). IRSs have at least six members (IRS-1 to IRS-6), where IRS-1 and IRS-2 are the most characterized [15]. SHc corresponds to at least three different proteins (SHcA, SHcB, and SHcC), with SHcA being expressed in mammals as the alternative splicing isoforms SHcA 46, SHcA 52, and SHcA 66 [16]. IRS-1 and IRS-2 are major activators of Akt via phosphatidylinositol 3 kinase (PI3K) compared with a minor effect on 44 and 42 kDa mitogen-activated protein kinases (p44/42mapk); instead, SHcA preferentially activates p44/42mapk via the growth factor receptor-bound protein 2 (Grb2) [17]. However, whether stimulation of IR-A or IR-B results in differential SHc or IRS activation and signalling is unknown. The physiological response of most tissues in the human body, including the foetoplacental vasculature, is that activation of p42/44mapk and Akt signalling pathways results in increased eNOS expression and activity leading to vasodilation [4, 18]. However, under pathological conditions, the equilibrium between signalling associated with IR-A and IR-B activation by insulin is lost and a preferential activation of p42/44mapk or Akt is reported. Several studies describe a variety of cell signalling mechanisms potentially involved in these alterations of insulin response; however, upstream- and downstream-associated signalling pathways are not addressed.

3. Insulin Resistance

Insulin resistance is seen in subjects where the metabolic handling of D-glucose is deficient [2]. PE [19, 20], GDM [21, 22], and obesity in pregnancy [23] show with insulin resistance in the mother, foetus, and newborn. However, whether insulin resistance results from or is the cause of these pathological conditions is still unclear.

Several studies show that IRS-1-mediated activation of PI3K leads to formation of phosphatidylinositol triphosphate, the substrate for the human 3-phosphoinositide-dependent protein kinase 1 (PDK1), which activates Akt [15] (Figure 2). However, in insulin resistance, IR-B preferential activation by insulin results in IRS1/2-mediated increase in the activity of the p85α regulatory subunit of PI3K (PI3K p85α), which inhibits Akt thus reducing NO generation. Other reports show that Akt activation mediates increased activity of the mammalian target of rapamycin (mTOR), a regulator of cell proliferation, adhesion, migration, invasion, metabolism, and survival [24]. Interestingly, mTOR signals through p70 S6 kinase 1 (S6K1) which reduces insulin signalling by inhibiting IRSs-activity-mediated activation of Akt [25, 26]. Thus, a modulatory loop to keep a physiological Akt activity and therefore insulin signalling to cause vasodilation involves mTOR activation/deactivation depending on the state of activation of Akt. When mTOR is upregulated, the physiological consequences are reduced Akt-mediated, NO-dependent vascular responses to insulin.

Other reports address that mTOR activity is inhibited by the adenosine monophosphate kinase (AMPK) [27], a molecule considered as general sensor of the cell energy state getting activated in response to a lower ATP/AMP ratio [28, 29]. AMPK activation results in increased eNOS activator phosphorylation at serine 1177 (Ser1177) and serine 615 (Ser615) in the vasculature [30]. Interestingly, AMPK activation increased the activity of PI3K/Akt/eNOS signalling cascade leading to higher NO generation and prevented the high D-glucose-impaired response to insulin in human umbilical vein endothelial cells (HUVECs) [31]. Thus, it is suggested that AMPK will increase insulin signalling due to its capacity to inhibit mTOR in the human foetoplacental vasculature.

Activation of p44/42mapk triggers c-Jun N-terminal kinase (JNK) signalling in HUVECs, resulting in IRS inhibition [32, 33] (Figure 2). Since S6K1 activation by mTOR results in p44/42mapk- and Akt-reduced activity in HUVECs [34] and insulin-dependent activation of p44/42mapk inhibits AMPK in the rat skeletal muscle cell line L6 [35], a functional dependency between p44/42mapk, AMPK, and mTOR activity may also be a phenomenon involved in impaired insulin sensitivity in the foetoplacental vasculature.

It is well described that proinflammatory cytokine tumour necrosis factor α (TNFα) [36] and the adipocytokine adiponectin [37] and leptin [38] play crucial roles in insulin resistance. TNFα activates the JNK signalling pathway in HUVECs [39] resulting in inhibition of IRS-1 and reduced Akt-mediated insulin signalling [4042] (Figure 2). Interestingly, higher plasma TNFα is found late in pregnancy (34–36 weeks of gestation) suggesting a likely reduced insulin biological action at this stage of pregnancy [43]. Adiponectin keeps insulin signalling (i.e., acts as insulin sensitizer) increasing the IRS-dependent signalling pathway by activating AMPK [37] and, subsequently, inhibiting mTOR [44]. Interestingly, a reduced plasma level of adiponectin is reported in pregnant women with diabetes mellitus [36]. Since the maternal plasma TNFα level is elevated in PE [45], GDM [46], or obese pregnant women [47], a potential TNFα-dependent inhibition of adiponectin release in insulin resistance in pregnant women, and perhaps the foetus, is likely. However, whether TNFα regulates adiponectin release in pregnancy is still unknown. Leptin is released in obesity in response to accumulating subcutaneous fat and increased fatty acid oxidation [38], a phenomenon regarded as a state of higher insulin resistance [38, 48]. Additionally, leptin activates JNK leading to inhibition of IRS1/2 and reduced insulin sensitivity [32, 33]. Since (i) leptin also increases the generation of reactive oxygen species (ROS) in HUVECs [49], (ii) superoxide anion (O2), the most reactive ROS, scavenges NO [30], and (iii) ROS activates JNK in this cell type [49], a leptin/ROS (probably O2)/JNK pathway is likely described as a mechanism leading to reduced insulin sensitivity in the human foetoplacental vasculature. Interestingly, increased leptin concentration in the maternal circulation is reported in GDM pregnancies [50, 51], a disease that also shows with increased ROS generation [9, 11]. Thus, this adipocytokine may also play a role in insulin resistance particularly in diseases of pregnancy where ROS generation is increased.

4. Insulin Resistance in Pregnancy Diseases

4.1. Preeclampsia

Preeclampsia (PE) is a heterogeneous pregnancy-specific multisystemic syndrome, defined by the occurrence of new onset hypertension (≥140/90 mmHg) and proteinuria (≥300 mg/24 hours) after 20 weeks of gestation [10, 52]. PE is of early onset (EOPE, <34 weeks of gestation) or late onset (LOPE, ≥34 weeks of gestation) [10, 53, 54]. EOPE and LOPE pregnancies associate with impaired insulin response of the maternal [55] and foetoplacental vasculature [20, 56]. However, not a clear mechanism explaining these alterations in EOPE and LOPE is yet available.

Preferential activation of p42/44mapk and Akt is described in the foetoplacental vasculature from PE. Preterm PE (<37 wg) with HELLP (Hemolysis, Elevated Liver enzymes, and Low Platelet count) courses with increased phosphorylated p42/44mapk activation in villous trophoblast [57]. In addition, the maternal plasma level from women with EOPE shows a higher level of endothelin-1 (ET-1) [58], but reduced Akt activity in the placenta [59] (Figure 3). Thus, an ET-1-dependent inhibition of Akt reducing insulin signalling is likely in this disease. Furthermore, since Akt activity positively correlates with NO generation in human foetal endothelial cells [60], EOPE-associated foetoplacental vascular dysfunction due to reduced NOS activity may involve p44/42mapk/ET-1/Akt signalling. On the other hand, LOPE pregnancies show with unaltered p42/44mapk [57] and unaltered [57] or decreased [61] Akt activity in the placenta. Intriguingly, eNOS protein abundance and activator phosphorylation (Ser1177) are higher in HUVECs from LOPE pregnancies [20], findings complemented by elevated nitrate/nitrite ratio in human umbilical vein serum [62, 63], but contrary to the reported lower nitrate/nitrite ratio [64] and NOS-generation of L-citrulline from L-arginine (index of NOS activity) [20] in this cell type. One plausible explanation for reduced NOS activity in HUVECs from LOPE pregnancies is a predominant functional effect of an increase of eNOS inhibitor (Thr495) compared with the effect of an activator (Ser1177) phosphorylation of this enzyme [20]. Earlier studies show increased IRS-1 (Ser312) and IRS-2 (Ser731) inhibitor phosphorylation in response to insulin in the placenta from LOPE pregnancies [65]. Since IRS1/2 are key activators of Akt, LOPE-reduced Akt and NOS activity could involve IRS1/2 inhibition. Thus, LOPE-associated impaired insulin response could result from reduced IRS1/2/Akt/eNOS signalling in the human foetoplacental vasculature. Since activation of mTOR results in reduced IRS1/2 activity, it is likely that this signalling molecule is involved in the effect of EOPE and LOPE on NOS activity. However, there is no information regarding the potential role of mTOR in the aetiology of EOPE or LOPE in this vascular bed.

Several reports support the involvement of circulating factors in the aetiology of PE including increased soluble Fms-like tyrosine kinase 1 (sFlt1), soluble endoglin (sEng), and reduced vascular endothelial growth factor (VEGF) plasma levels [66, 67]. The increased plasma levels of ET-1 and sEng result in a higher sFlt1 plasma level [68]. The latter reduces the availability of free VEGF-A to bind VEGF plasma membrane receptors and inhibition of PI3K/Akt signalling, including eNOS activity, in HUVECs [61, 69]. However, inhibition of the PI3K/Akt signalling does not alter sEng release from placenta explants or primary trophoblast in PE [59]; therefore, a differential response to PI3K/Akt-mediated insulin signalling in human foetoplacental endothelium versus trophoblast is likely. Interestingly, PI3K p85 phosphorylation at Tyr688 results in increased PI3K activity and Akt signalling in placental tissue from EOPE pregnancies [70]. The latter was proposed as a compensatory mechanism to the VEGF-reduced activation of PI3K/Akt signalling in this disease. However, PI3K p85 activator phosphorylation is unaltered in placentas from LOPE pregnancies [71], suggesting a different adaptive mechanism for insulin signalling in EOPE and LOPE pregnancies.

4.2. Gestational Diabetes Mellitus

GDM refers to any degree of glucose intolerance first recognized during pregnancy, diagnosed at 24–28 weeks of gestation [2]. GDM associates with maternal obesity [72] and high risk of the mother to develop T2DM [73]. GDM presents with clinical manifestations in the mother [74], foetus [75, 76], and newborn [75, 77], including hyperglycaemia and hyperinsulinemia (see also [78, 79]). It is reported that IR-A expression and insulin receptor β-subunit (β-IR) activity are increased in HUVECs from GDM [80] (Figure 3). Interestingly, the ratio for p44/42mapk/Akt is >1 due to increased p44/44mapk, but unaltered Akt activity, suggesting preferential activation of IR-A in this cell type. However, reduced IR-A, but increased IR-B expression, with a p44/42mapk/Akt ratio < 1 was reported in human placental microvascular endothelium. Insulin restored IR-A and IR-B expression and p44/42mapk/Akt ratio suggesting differential activation of insulin signalling cascades due to differential activation of IR subtypes in the macrovascular and microvascular foetoplacental endothelium from GDM pregnancies.

GDM associates with reduced uptake of the endogenous nucleoside adenosine, a potent vasodilator in most tissues, including the foetoplacental vasculature [4]. This phenomenon results in elevated extracellular concentration of adenosine enough to activate adenosine receptors [81], preferentially A2A adenosine receptors (A2AAR), in the foetoplacental endothelium from GDM pregnancies [4, 11]. Interestingly, GDM also increases hCAT-1-mediated L-arginine transport in HUVECs [82], which seems to link with an increased eNOS activity and NO synthesis in this cell type. The latter study also shows that insulin reversed the GDM-increased L-arginine transport requiring A1AR activation. Thus, different adenosine receptors are involved in the modulation of L-arginine transport in HUVECs from normal compared with GDM pregnancies.

AMPK activation is lower in the placenta from women with GDM [83, 84]. This finding is complemented by high levels of TNF-α and activation of NF-κB, conditions leading to increased synthesis of mediators of inflammation and impaired insulin action [85, 86]. Thus, reduced AMPK expression could associate with a proinflammatory state and insulin resistance in GDM pregnancies. Since AMPK inhibits mTOR activity [27, 44], a reduced AMPK activation could result in increased mTOR activity in GDM. GDM also courses with hyperleptinemia in the placenta [87, 88] and reduced adiponectin level [89] in umbilical vein plasma. However, precise mechanisms at insulin signalling in this disease are unclear.

Insulin treatment of women with GDM (i.e., patients under insulin therapy) reverses the GDM-associated maternal and foetal hyperglycaemia and the increase in IRS-1 and PI3K p85α activity caused by this disease to values in normal pregnancies [90]. However, the elevated level of leptin in the foetal plasma and TNF-α and IL-1β levels in the placenta from GDM pregnancies were unaltered by insulin therapy. Thus, insulin therapy results in normalization of foetal and maternal glycaemia but does not restore the impaired insulin signalling in foetoplacental endothelium in this disease. Indeed, we recently reported that insulin therapy in women with GDM did not restore the increased L-arginine uptake and NO synthesis seen in HUVECs from women with GDM under a controlled diet [91]. It is worrying that a higher chance to be born large for gestational age is reported as an outcome for insulin therapy [92] or in pregnant women treated with insulin and metformin [93] and in a larger number (~25%) of infants showing one or more episodes with neonatal morbidity where neonatal asymptomatic hypoglycaemia was the most frequent [94]. We emphasize our call regarding the still unclear effect of maternal insulin therapy on foetus development, the newborn, and postnatal life [2, 4, 9, 91, 95].

4.3. Pregestational Maternal Obesity

The World Health Organization defines obesity as individuals with a body mass index (BMI) > 30 kg/m2, a disease that has reached epidemic characteristics worldwide [1]. One of the main risks of an abnormal nutritional state is its association with metabolic syndrome, a condition with high multiple risk factors for chronic diseases, including diabetes mellitus, cardiovascular diseases, stroke, hypertension, and cancer [96].

Few studies address cell signalling in PGMO. Epidemiological evidence shows that children born to PGMO pregnancies show hyperinsulinemia and elevated insulin resistance [97, 98]. Additionally, infants and adolescents from PGMO pregnancies exhibit high risk of developing obesity [99, 100] and associate with higher cardiovascular risk in adulthood [100]. Interestingly, umbilical cords from PGMO pregnancies show a gene profile related with reduced insulin sensitivity [101], including downregulation of PDPK1 (coding for PDK1) involved in D-glucose uptake and storage [101]. However, direct functional evidence for insulin effect on foetoplacental endothelium in PGMO is limited (Table 1).


Cell or tissueMolecule or activityEffect of the pathologyEffect of insulinReferences

Preeclampsia
Placenta (EOPE)p44/42mapkIncreasena[57]
Placenta (EOPE)ET-1, ETA, and ETB (mRNA)Increasena[108]
PlacentaAkt-Ser473Decreasena[61]
PlacentaeNOSIncreasena[109]
Placenta (LOPE)β-IR, IRS-1-Tyr465, IRS-1-Ser312, and IRS-2-Ser731No effectIncrease[65]
Placenta (LOPE)Akt-Ser473No effectIncrease[110]
HUVECs (LOPE)eNOS-Thr495, eNOS-Ser1177IncreaseRestored[20]
HUVECs (LOPE)eNOS-Ser1177Increasena[111]
HUVECs (EOPE)eNOSDecreasena[111]
HUVECseNOSDecreasena[112]
HUVECs (LOPE)L-Arginine transportIncreaseRestored[20]
HUVECs (LOPE)hCAT-1IncreaseIncrease[20]
Gestational diabetes mellitus
PlacentaIRsIncreasena[113]
Placenta (insulin therapy)β-IRIncreaseRestored[90]
PlacentaIRS-1Increasena[113]
Placenta (insulin therapy)IRS-1IncreaseRestored[90]
Placenta (insulin therapy)IRS-2IncreaseIncrease[90]
PlacentaPI3K p85αIncreaseRestored[90]
PlacentaPI3K p85αIncreasena[113]
Placenta (insulin therapy)PI3K p110IncreaseNo effect[90]
PlacentamTOR-Ser2448, S6K1-Thr421/Ser424Increasena[83]
PlacentaS6 K1-Thr389, 4EBP1-Thr37/46Increasena[114]
Placenta4EBP1-Thr37/46Increasena[83]
PlacentaAMPK (mRNA)Decreasena[88]
PlacentaAdiponectinDecreasena[115]
PlacentaTNF-αIncreasena[85, 116]
Placenta (insulin therapy)TNF-αUnalteredna[86]
PlacentaIL-1βIncreasena[116]
PlacentaLeptin receptorIncreasena[88]
TrophoblastLeptin receptorIncreasena[87]
HUVECsIR-A (mRNA)IncreaseRestored[21]
HUVECsAkt-Ser473No effectIncrease[80]
HUVECseNOS, eNOS-Ser1177IncreaseRestored[80]
HUVECsp44/42mapk-Thr202/204IncreaseRestored[80]
HUVECs (insulin therapy)eNOS, eNOS-Ser1177IncreaseRestored[117]
HUVECshENT1, adenosine transportDecreaseIncrease[21, 80]
HUVECsL-Arginine transportIncreaseRestored[82]
HUVECs (insulin therapy)L-Arginine transportIncreaseRestored[117]
hPMECsp44/42mapk-Thr202/204, Akt-Ser473DecreaseRestored[118]
hPMECsIR-A (mRNA)DecreaseRestored[118]
hPMECsIR-B (mRNA)IncreaseRestored[118]
hPMECshENT1DecreaseNo effect[118]
hPMECshENT2DecreaseRestored[118]
hPMECshENT1 transport activityDecreaseNo effect[118]
hPMECshENT2 transport activityDecreaseRestored[118]
Umbilical cord plasmaLeptinIncreasena[88]
Umbilical cord plasmaAdiponectinDecreasena[89]
Pregestational maternal obesity
PlacentaAMPK-Thr172Decreasena[102, 103]
PlacentaAMPKDecreasena[103]
PlacentaS6 K1-Thr389Increasena[88, 119]
PlacentaJNK-Thr183/Tyr185Increasena[119]
PlacentamTOR (mRNA)Decreasena[102, 103]
PlacentaIRS-1 (mRNA)Decreasena[103]

AMPK: adenosine monophosphate protein kinase; AMPK-Thr172: AMPK phosphorylated at threonine 172; S6K1: S6 kinase 1; S6K1-Thr421/Ser424: S6K1 phosphorylated at threonine 421 and serine 424; S6K1-Thr389: S6K1 phosphorylated at threonine 389; JNK: c-Jun N-terminal kinases; JNK-Thr183/Tyr185: JNK phosphorylated at threonine 183 and tyrosine 185; mTOR: mammalian target of rapamycin; IRS-1: insulin receptor substrate 1; IRS-1-Tyr465: IRS-1 phosphorylated at tyrosine 465; IRS-1-Ser312: IRS-1 phosphorylated at serine 312; IRS-2: insulin receptor substrate 2; IRS-2-Ser731: IRS-2 phosphorylated at serine 731; EOPE: early-onset preeclampsia; LOPE: late-onset preeclampsia; p44/42mapk: 44 and 42 kDa mitogen-activated protein kinases; p44/42mapk-Thr202/204: p44mapk phosphorylated at threonine 202 and p42mapk phosphorylated at threonine 204; Akt: protein kinase B/Akt; Akt-Ser473: Akt phosphorylated at serine 473; eNOS: endothelial nitric oxide synthase; eNOS-Thr495: eNOS phosphorylated at threonine 495; eNOS-Ser1177: eNOS phosphorylated at serine 1177; IRs: insulin receptors; IR-A: insulin receptor A; IR-B: insulin receptor B; β-IR: insulin receptor β-subunit; PI3K: phosphatidylinositol 3 kinase; PI3K p85α: p85α regulatory subunit of PI3K; PI3K p110: p110 catalytic subunit of PI3K; EGFR: epidermal growth factor receptor; mTOR-Ser2448: mTOR phosphorylated at serine 2448; S6K1-Tyr389: S6K1 phosphorylated at threonine 389; 4EBP1: eukaryotic translation initiation factor 4E binding protein 1; 4EBP1-Thr37/46: 4EBP1 phosphorylated at threonine 37 and 46; TNF-α: tumour necrosis factor α; AP1: activator protein 1; NF-κB: nuclear factor-kappa B; ET-1: endothelin 1; ETA: endothelin receptor type A; ETB: endothelin receptor type B; IL-1β: interleukin 1β; hCAT-1: human cationic amino acid transporter 1; hENT1: human equilibrative nucleoside transporters 1; hENT2: human equilibrative nucleoside transporters 2; HUVECs: human umbilical vein endothelial cells; hPMECs: human placental microvascular endothelial cells. Cells incubated with insulin in the presence of ZM-241385 (A2AAR antagonist). GDM mothers were obese. Results include GDM mother under diet and insulin therapy. GDM mother on oral insulin-sensitizing antidiabetic undefined medication. na: not assayed.

PGMO pregnancies associate with reduced activity of AMPK [102] but increased activity of mTOR [103] in the placenta. These findings correlate with reduced maternal plasma adiponectin levels [104]. Since JNK activation is also increased in human placentas from PGMO pregnancies [105], a potential insulin resistance condition resulting from IRS inhibition may involve adiponectin-reduced level-dependent AMPK inactivation, increased mTOR activity, and reduced Akt signalling, in this abnormal condition of pregnancy (Figure 3).

5. Concluding Comments

Insulin regulates canonical signal transduction pathways initiated by activation of IR-A/p44/42mapk and IR-B/Akt in human foetoplacental vasculature in healthy pregnancies (Figure 3). IRS-1 and IRS-2 are upstream activators of the PI3K/Akt signalling pathway leading to activation of mTOR. SHcA 42 and SHcA 56 activate p44/42mapk leading to increased release of vasoconstrictors, such as ET-1. Insulin resistance associated with PGMO, PE, and GDM results in foetoplacental vascular dysfunction and altered vascular reactivity to insulin. A likely potential common point in insulin resistance in these diseases is a reduced Akt signalling resulting in lower activation of mTOR and eNOS. A role for AMPK in this phenomenon is not clear, but the involvement of this molecule is likely since its activation positively correlates with mTOR activity. A role of NO in the response to insulin in the foetoplacental endothelium in diseases of pregnancy is well described [4, 10, 12]. Thus, modulation of NO generation could be a final target of an abnormal IR-A/SHcA/p44/42mapk- and IR-B/IRSs/Akt-mediated signalling via Akt/mTOR in insulin resistance at the human foetoplacental vasculature. A therapy targeting these signalling molecules could be beneficial to improve insulin response in these diseases. PGMO is a risk factor for developing PE [106, 107] and GDM [107]. Thus, characterizing potential common signalling mechanisms for PGMO, PE, and GDM will facilitate the design of an approach to prevent insulin resistance in the co-occurrence of these or other disorders in pregnancy, thus reducing or abolishing their deleterious consequences for the mother, the foetus, and the newborn.

Conflicts of Interest

The authors confirm that there are no conflicts of interest.

Authors’ Contributions

Roberto Villalobos-Labra, Luis Silva, and Luis Sobrevia conceived and designed the study. Roberto Villalobos-Labra, Mario Subiabre, Luis Silva, Joaquín Araos, Tamara Sáez, Bárbara Fuenzalida, Marcelo González, Rocío Salsoso, and Andrea Leiva acquired the data/information. Roberto Villalobos-Labra, Mario Subiabre, Luis Silva, Fernando Toledo, Delia I. Chiarello, Joaquín Araos, Tamara Sáez, Bárbara Fuenzalida, Marcelo González, Fabían Pardo, Rocío Salsoso, Claudia Quezada, Andrea Leiva, and Luis Sobrevia analyzed the data/information. Roberto Villalobos-Labra, Mario Subiabre, Luis Silva, Rocío Salsoso, Joaquín Araos, Bárbara Fuenzalida, Fabían Pardo, Claudia Quezada, Andrea Leiva, and Luis Sobrevia interpreted the data/information. Roberto Villalobos-Labra, Mario Subiabre, Luis Silva, Rocío Salsoso, and Luis Sobrevia compiled the tables. Roberto Villalobos-Labra, Luis Silva, and Luis Sobrevia designed the figures. Roberto Villalobos-Labra, Luis Silva, and Luis Sobrevia wrote the manuscript.

Acknowledgments

The authors thank Mrs. Amparo Pacheco from CMPL, Pontificia Universidad Católica de Chile (PUC), for the excellent technical and secretarial assistance. This work was supported by the Fondo Nacional de Desarrollo Científico y Tecnológico (FONDECYT 1150377, 1150344, 3160194, 11150083), Chile. This project has received funding from the Marie Curie International Research Staff Exchange Scheme with the 7th European Community Framework Program (Grant Agreement no. 295185–EULAMDIMA), the Netherlands. Roberto Villalobos-Labra, Mario Subiabre, Luis Silva, Tamara Sáez, and Rocío Salsoso hold the Comisión Nacional de Investigación en Ciencia y Tecnología (CONICYT) PhD fellowships (Chile). Rocío Salsoso, Luis Silva, and Bárbara Fuenzalida hold Faculty of Medicine, PUC–PhD fellowships (Chile). Tamara Sáez and Luis Silva hold UMCG University of Groningen Postgraduate School-PhD fellowships (the Netherlands).

References

  1. American Diabetes Association (ADA), “Classification and diagnosis of diabetes,” Diabetes Care, vol. 40, pp. S11–S24, 2017. View at: Google Scholar
  2. World Health Organization (WHO), “Global status report on noncommunicable diseases 2014,” World Health, vol. 176, 2014. View at: Google Scholar
  3. R. Muniyappa and J. R. Sowers, “Role of insulin resistance in endothelial dysfunction,” Reviews in Endocrine & Metabolic Disorders, vol. 14, pp. 5–12, 2013. View at: Publisher Site | Google Scholar
  4. L. Silva, M. Subiabre, J. Araos et al., “Insulin/adenosine axis linked signalling,” Molecular Aspects of Medicine, vol. 55, pp. 45–61, 2017. View at: Publisher Site | Google Scholar
  5. A. D. Sonagra, S. M. Biradar, K. Dattatreya, and D. S. J. Murthy, “Normal pregnancy- a state of insulin resistance,” Journal of Clinical and Diagnostic Research, vol. 8, pp. CC01–CC03, 2014. View at: Publisher Site | Google Scholar
  6. K. J. Mather, H. O. Steinberg, and A. D. Baron, “Insulin resistance in the vasculature,” The Journal of Clinical Investigation, vol. 123, pp. 1003-1004, 2013. View at: Publisher Site | Google Scholar
  7. S. B. Fox and T. Y. Khong, “Lack of innervation of human umbilical cord. An immunohistological and histochemical study,” Placenta, vol. 11, pp. 59–62, 1990. View at: Google Scholar
  8. M. S. Hanson, A. H. Stephenson, E. A. Bowles, and R. S. Sprague, “Insulin inhibits human erythrocyte cAMP accumulation and ATP release: role of phosphodiesterase 3 and phosphoinositide 3-kinase,” Experimental Biology and Medicine, vol. 235, pp. 256–262, 2010. View at: Publisher Site | Google Scholar
  9. L. Sobrevia, R. Salsoso, T. Sáez, C. Sanhueza, F. Pardo, and A. Leiva, “Insulin therapy and fetoplacental vascular function in gestational diabetes mellitus,” Experimental Physiology, vol. 100, pp. 231–238, 2015. View at: Publisher Site | Google Scholar
  10. R. Salsoso, M. Farías, J. Gutiérrez et al., “Adenosine and preeclampsia,” Molecular Aspects of Medicine, vol. 55, pp. 126–139, 2017. View at: Publisher Site | Google Scholar
  11. L. Antonioli, C. Blandizzi, B. Csóka, P. Pacher, and G. Haskó, “Adenosine signalling in diabetes mellitus—pathophysiology and therapeutic considerations,” Nature Reviews. Endocrinology, vol. 11, pp. 228–241, 2015. View at: Publisher Site | Google Scholar
  12. F. Pardo, R. Villalobos-Labra, D. I. Chiarello et al., “Molecular implications of adenosine in obesity,” Molecular Aspects of Medicine, vol. 55, pp. 90–101, 2017. View at: Publisher Site | Google Scholar
  13. F. Westermeier, T. Sáez, P. Arroyo et al., “Insulin receptor isoforms: an integrated view focused on gestational diabetes mellitus,” Diabetes/Metabolism Research and Reviews, vol. 32, pp. 350–365, 2016. View at: Publisher Site | Google Scholar
  14. L. Mosthaf, K. Grako, T. J. Dull, L. Coussens, A. Ullrich, and M. C. DA, “Functionally distinct insulin receptors generated by tissue-specific alternative splicing,” The EMBO Journal, vol. 9, pp. 2409–2413, 1990. View at: Google Scholar
  15. J. Boucher, A. Kleinridders, and C. R. Kahn, “Insulin receptor signaling in normal and insulin-resistant states,” Cold Spring Harbor Perspectives in Biology, vol. 6, article a009191, 2014. View at: Publisher Site | Google Scholar
  16. K. S. Ravichandran, “Signaling via Shc family adapter proteins,” Oncogene, vol. 20, pp. 6322–6330, 2001. View at: Publisher Site | Google Scholar
  17. S. H. Ong, Y. R. Hadari, N. Gotoh, G. R. Guy, J. Schlessinger, and I. Lax, “Stimulation of phosphatidylinositol 3-kinase by fibroblast growth factor receptors is mediated by coordinated recruitment of multiple docking proteins,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, pp. 6074–6079, 2001. View at: Publisher Site | Google Scholar
  18. L. Sobrevia, R. Salsoso, B. Fuenzalida et al., “Insulin is a key modulator of fetoplacental endothelium metabolic disturbances in gestational diabetes mellitus,” Frontiers in Physiology, vol. 7, p. 119, 2016. View at: Publisher Site | Google Scholar
  19. J. M. Roberts, L. M. Bodnar, T. E. Patrick, and R. W. Powers, “The role of obesity in preeclampsia,” Pregnancy Hypertens, vol. 1, pp. 6–16, 2011. View at: Publisher Site | Google Scholar
  20. R. Salsoso, E. Guzmán-Gutiérrez, T. Sáez et al., “Insulin restores l-arginine transport requiring adenosine receptors activation in umbilical vein endothelium from late-onset preeclampsia,” Placenta, vol. 36, pp. 287–296, 2015. View at: Publisher Site | Google Scholar
  21. F. Westermeier, C. Salomón, M. González et al., “Insulin restores gestational diabetes mellitus-reduced adenosine transport involving differential expression of insulin receptor isoforms in human umbilical vein endothelium,” Diabetes, vol. 60, pp. 1677–1687, 2011. View at: Publisher Site | Google Scholar
  22. Q. Wang, R. Huang, B. Yu et al., “Higher fetal insulin resistance in Chinese pregnant women with gestational diabetes mellitus and correlation with maternal insulin resistance,” PLoS One, vol. 8, article e59845, 2013. View at: Publisher Site | Google Scholar
  23. F. Pardo, L. Silva, T. Sáez et al., “Human supraphysiological gestational weight gain and fetoplacental vascular dysfunction,” International Journal of Obesity, vol. 39, pp. 1264–1273, 2015. View at: Publisher Site | Google Scholar
  24. J. Karar and A. Maity, “PI3K/AKT/mTOR pathway in angiogenesis,” Frontiers in Molecular Neuroscience, vol. 4, p. 51, 2011. View at: Publisher Site | Google Scholar
  25. A. Tzatsos, “Raptor binds the SAIN (Shc and IRS-1 NPXY binding) domain of insulin receptor substrate-1 (IRS-1) and regulates the phosphorylation of IRS-1 at Ser-636/639 by mTOR,” The Journal of Biological Chemistry, vol. 284, pp. 22525–22534, 2009. View at: Publisher Site | Google Scholar
  26. S. J. Kim, M. A. DeStefano, W. J. Oh et al., “mTOR complex 2 regulates proper turnover of insulin receptor substrate-1 via the ubiquitin ligase subunit Fbw8,” Molecular Cell, vol. 48, pp. 875–887, 2012. View at: Publisher Site | Google Scholar
  27. M. M. Mihaylova and R. J. Shaw, “The AMPK signalling pathway coordinates cell growth, autophagy and metabolism,” Nature Cell Biology, vol. 13, pp. 1016–1023, 2011. View at: Publisher Site | Google Scholar
  28. B. Fisslthaler and I. Fleming, “Activation and signaling by the AMP-activated protein kinase in endothelial cells,” Circulation Research, vol. 105, pp. 114–127, 2009. View at: Publisher Site | Google Scholar
  29. D. G. Hardie and F. A. RossS. A. Hawley, “AMPK: a nutrient and energy sensor that maintains energy homeostasis,” Nature Reviews. Molecular Cell Biology, vol. 13, pp. 251–262, 2012. View at: Publisher Site | Google Scholar
  30. I. Fleming, “Molecular mechanisms underlying the activation of eNOS,” Pflugers Archiv-European Journal of Physiology, vol. 459, pp. 793–806, 2010. View at: Publisher Site | Google Scholar
  31. Y. Ido, D. Carling, and N. Ruderman, “Hyperglycemia-induced apoptosis in human umbilical vein endothelial cells: inhibition by the AMP-activated protein kinase activation,” Diabetes, vol. 51, pp. 159–167, 2002. View at: Google Scholar
  32. F. Andreozzi, E. Laratta, A. Sciacqua, F. Perticone, and G. Sesti, “Angiotensin II impairs the insulin signaling pathway promoting production of nitric oxide by inducing phosphorylation of insulin receptor substrate-1 on Ser312 and Ser616 in human umbilical vein endothelial cells,” Circulation Research, vol. 94, pp. 1211–1218, 2004. View at: Publisher Site | Google Scholar
  33. V. De Nigris, G. Pujadas, L. La Sala, R. Testa, S. Genovese, and A. Ceriello, “Short-term high glucose exposure impairs insulin signaling in endothelial cells,” Cardiovascular Diabetology, vol. 14, p. 114, 2015. View at: Publisher Site | Google Scholar
  34. F. Pellegatta, A. L. Catapano, L. Luzi, and I. Terruzzi, “In human endothelial cells amino acids inhibit insulin-induced Akt and ERK1/2 phosphorylation by an mTOR-dependent mechanism,” Journal of Cardiovascular Pharmacology, vol. 47, pp. 643–649, 2006. View at: Publisher Site | Google Scholar
  35. S. L. Hwang, Y. T. Jeong, X. Li et al., “Inhibitory cross-talk between the AMPK and ERK pathways mediates endoplasmic reticulum stress-induced insulin resistance in skeletal muscle,” British Journal of Pharmacology, vol. 169, pp. 69–81, 2013. View at: Publisher Site | Google Scholar
  36. L. A. Barbour, C. E. McCurdy, T. L. Hernandez, J. P. Kirwan, P. M. Catalano, and J. E. Friedman, “Cellular mechanisms for insulin resistance in normal pregnancy and gestational diabetes,” Diabetes Care, vol. 30, pp. 112–119, 2007. View at: Publisher Site | Google Scholar
  37. H. Ruan and L. Q. Dong, “Adiponectin signaling and function in insulin target tissues,” Journal of Molecular Cell Biology, vol. 8, pp. 101–109, 2016. View at: Publisher Site | Google Scholar
  38. A. Yadav, M. A. Kataria, V. Saini, and A. Yadav, “Role of leptin and adiponectin in insulin resistance,” Clinica Chimica Acta, vol. 417, pp. 80–84, 2013. View at: Publisher Site | Google Scholar
  39. J. Surapisitchat, R. J. Hoefen, X. Pi, M. Yoshizumi, C. Yan, and B. C. Berk, “Fluid shear stress inhibits TNF-alpha activation of JNK but not ERK1/2 or p38 in human umbilical vein endothelial cells: inhibitory crosstalk among MAPK family members,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, pp. 6476–6481, 2001. View at: Publisher Site | Google Scholar
  40. V. Aguirre, T. Uchida, L. Yenush, R. Davis, and M. F. White, “The c-Jun NH2-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser307,” The Journal of Biological Chemistry, vol. 275, pp. 9047–9054, 2000. View at: Google Scholar
  41. Y. H. Lee, J. Giraud, R. J. Davis, and M. F. White, “c-Jun N-terminal kinase (JNK) mediates feedback inhibition of the insulin signaling cascade,” The Journal of Biological Chemistry, vol. 278, pp. 2896–2902, 2003. View at: Publisher Site | Google Scholar
  42. K. Hiratani, T. Haruta, A. Tani, J. Kawahara, I. Usui, and M. Kobayashi, “Roles of mTOR and JNK in serine phosphorylation, translocation, and degradation of IRS-1,” Biochemical and Biophysical Research Communications, vol. 335, pp. 836–842, 2005. View at: Publisher Site | Google Scholar
  43. J. P. Kirwan, S. Hauguel-De Mouzon, J. Lepercq et al., “TNF-alpha is a predictor of insulin resistance in human pregnancy,” Diabetes, vol. 51, pp. 2207–2213, 2002. View at: Google Scholar
  44. A. S. Lihn, S. B. Pedersen, and B. Richelsen, “Adiponectin: action, regulation and association to insulin sensitivity,” Obesity Reviews, vol. 6, pp. 13–21, 2005. View at: Publisher Site | Google Scholar
  45. S. S. Huda, L. E. Brodie, and N. Sattar, “Obesity in pregnancy: prevalence and metabolic consequences,” Seminars in Fetal & Neonatal Medicine, vol. 15, pp. 70–76, 2010. View at: Publisher Site | Google Scholar
  46. G. Winkler, K. Cseh, E. Baranyi et al., “Tumor necrosis factor system in insulin resistance in gestational diabetes,” Diabetes Research and Clinical Practice, vol. 56, pp. 93–99, 2002. View at: Google Scholar
  47. A. Molvarec, A. Szarka, S. Walentin et al., “Serum leptin levels in relation to circulating cytokines, chemokines, adhesion molecules and angiogenic factors in normal pregnancy and preeclampsia,” Reproductive Biology and Endocrinology, vol. 9, p. 124, 2011. View at: Publisher Site | Google Scholar
  48. H. Askari, G. Tykodi, J. Liu, and S. Dagogo-Jack, “Fasting plasma leptin level is a surrogate measure of insulin sensitivity,” The Journal of Clinical Endocrinology and Metabolism, vol. 95, pp. 3836–3843, 2010. View at: Publisher Site | Google Scholar
  49. A. Bouloumie, T. Marumo, M. Lafontan, and R. Busse, “Leptin induces oxidative stress in human endothelial cells,” The FASEB Journal, vol. 13, pp. 1231–1238, 1999. View at: Google Scholar
  50. A. Kautzky-Willer, G. Pacini, A. Tura et al., “Increased plasma leptin in gestational diabetes,” Diabetologia, vol. 44, pp. 164–172, 2001. View at: Publisher Site | Google Scholar
  51. J. M. Atègbo, O. Grissa, A. Yessoufou et al., “Modulation of adipokines and cytokines in gestational diabetes and macrosomia,” The Journal of Clinical Endocrinology and Metabolism, vol. 91, pp. 4137–4143, 2006. View at: Publisher Site | Google Scholar
  52. B. Sibai, G. Dekker, and M. Kupferminc, “Pre-eclampsia,” Lancet (London, England), vol. 365, pp. 785–799, 2005. View at: Publisher Site | Google Scholar
  53. A. L. Tranquilli, M. A. Brown, G. G. Zeeman, G. Dekker, and B. M. Sibai, “The definition of severe and early-onset preeclampsia. Statements from the International Society for the Study of Hypertension in Pregnancy (ISSHP),” Pregnancy Hypertens, vol. 3, pp. 44–47, 2013. View at: Publisher Site | Google Scholar
  54. American College of Obstetrics and Gynecology (ACOG), “Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy,” Obstetrics and Gynecology, vol. 122, pp. 1122–1131, 2013. View at: Publisher Site | Google Scholar
  55. F. R. Abhari, M. Ghanbari Andarieh, A. Farokhfar, and S. Ahmady, “Estimating rate of insulin resistance in patients with preeclampsia using HOMA-IR index and comparison with nonpreeclampsia pregnant women,” BioMed Research International, vol. 2014, Article ID 140851, 6 pages, 2014. View at: Publisher Site | Google Scholar
  56. M. Scioscia, S. A. Karumanchi, D. Goldman-Wohl, and P. Y. Robillard, “Endothelial dysfunction and metabolic syndrome in preeclampsia: an alternative viewpoint,” Journal of Reproductive Immunology, vol. 108, pp. 42–47, 2015. View at: Publisher Site | Google Scholar
  57. S. Szabo, M. Mody, R. Romero et al., “Activation of villous trophoblastic p38 and ERK1/2 signaling pathways in preterm preeclampsia and HELLP syndrome,” Pathology Oncology Research, vol. 21, pp. 659–668, 2015. View at: Publisher Site | Google Scholar
  58. L. Zhang, Y. Han, and Y. Han, “Serum soluble endoglin, plasma endothelin-1 and coagulation function in early onset severe preeclampsia with organ dysfunction,” Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, vol. 22, pp. 371–374, 2010. View at: Google Scholar
  59. T. J. Kaitu’u-Lino, R. Hastie, N. J. Hannan et al., “Loss of Akt increases soluble endoglin release from endothelial cells but not placenta,” Pregnancy Hypertens, vol. 6, pp. 95–102, 2016. View at: Publisher Site | Google Scholar
  60. N. L. Huang, S. H. Chiang, C. H. Hsueh, Y. J. Liang, Y. J. Chen, and L. P. Lai, “Metformin inhibits TNF-α-induced IκB kinase phosphorylation, IκB-α degradation and IL-6 production in endothelial cells through PI3K-dependent AMPK phosphorylation,” International Journal of Cardiology, vol. 134, pp. 169–175, 2009. View at: Publisher Site | Google Scholar
  61. M. J. Cudmore, S. Ahmad, S. Sissaoui et al., “Loss of Akt activity increases circulating soluble endoglin release in preeclampsia: identification of inter-dependency between Akt-1 and heme oxygenase-1,” European Heart Journal, vol. 33, pp. 1150–1158, 2012. View at: Publisher Site | Google Scholar
  62. A. H. Shaamash, E. D. Elsnosy, A. M. Makhlouf, M. M. Zakhari, O. A. Ibrahim, and E L.-d. HM, “Maternal and fetal serum nitric oxide (NO) concentrations in normal pregnancy, pre-eclampsia and eclampsia,” International Journal of Gynaecology and Obstetrics, vol. 68, pp. 207–214, 2000. View at: Google Scholar
  63. S. Demircan Sezer, M. Küçük, S. Nergiz Avcıoğlu et al., “Comparison of maternal and umbilical cord blood HIF-1α and nitric oxide levels in early and late onset preeclamptic pregnancies,” Gynecological Endocrinology, vol. 31, pp. 945–948, 2015. View at: Publisher Site | Google Scholar
  64. J. A. Gonzalez-Garrido Chem, I. M. Olivares-Corichi, J. M. Tovar-Rodriguez et al., “Influence of the AT(2) receptor on the L-arginine-nitric oxide pathway and effects of (-)-epicatechin on HUVECs from women with preeclampsia,” Journal of Human Hypertension, vol. 27, pp. 355–361, 2013. View at: Publisher Site | Google Scholar
  65. M. Scioscia, K. Gumaa, S. Kunjara et al., “Insulin resistance in human preeclamptic placenta is mediated by serine phosphorylation of insulin receptor substrate-1 and -2,” The Journal of Clinical Endocrinology and Metabolism, vol. 91, pp. 709–717, 2006. View at: Publisher Site | Google Scholar
  66. S. E. Maynard and S. A. Karumanchi, “Angiogenic factors and preeclampsia,” Seminars in Nephrology, vol. 31, pp. 33–46, 2011. View at: Publisher Site | Google Scholar
  67. S. Rana, S. A. Karumanchi, and M. D. Lindheimer, “Angiogenic factors in diagnosis, management, and research in preeclampsia,” Hypertension, vol. 63, pp. 198–202, 2014. View at: Publisher Site | Google Scholar
  68. K. Verdonk, L. Saleh, S. Lankhorst et al., “Association studies suggest a key role for endothelin-1 in the pathogenesis of preeclampsia and the accompanying renin-angiotensin-aldosterone system suppression,” Hypertension, vol. 65, pp. 1316–1323, 2015. View at: Publisher Site | Google Scholar
  69. T. Cindrova-Davies, D. A. Sanders, G. J. Burton, and D. S. Charnock-Jones, “Soluble FLT1 sensitizes endothelial cells to inflammatory cytokines by antagonizing VEGF receptor-mediated signalling,” Cardiovascular Research, vol. 89, pp. 671–679, 2011. View at: Publisher Site | Google Scholar
  70. B. D. Cuevas, Y. Lu, M. Mao et al., “Tyrosine phosphorylation of p85 relieves its inhibitory activity on phosphatidylinositol 3-kinase,” The Journal of Biological Chemistry, vol. 276, pp. 27455–27461, 2001. View at: Publisher Site | Google Scholar
  71. R. B. Orcy, S. Schroeder, S. Hofmeister Martins-Costa et al., “Signalization of Akt/PKB in the placenta, skeletal muscle and adipose tissue of preeclampsia patients,” Gynecologic and Obstetric Investigation, vol. 66, pp. 231–236, 2008. View at: Publisher Site | Google Scholar
  72. S. Y. Chu, W. M. Callaghan, S. Y. Kim et al., “Maternal obesity and risk of gestational diabetes mellitus,” Diabetes Care, vol. 30, pp. 2070–2076, 2007. View at: Publisher Site | Google Scholar
  73. L. Bellamy, J.-P. Casas, A. D. Hingorani, and D. Williams, “Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis,” Lancet, vol. 373, pp. 1773–1779, 2009. View at: Publisher Site | Google Scholar
  74. P. M. Catalano, E. D. Tyzbir, R. R. Wolfe et al., “Carbohydrate metabolism during pregnancy in control subjects and women with gestational diabetes,” The American Journal of Physiology, vol. 264, pp. E60–E67, 1993. View at: Google Scholar
  75. B. L. Silverman, B. E. Metzger, N. H. Cho, and C. A. Loeb, “Impaired glucose tolerance in adolescent offspring of diabetic mothers: relationship to fetal hyperinsulinism,” Diabetes Care, vol. 18, pp. 611–617, 1995. View at: Google Scholar
  76. C. Y. Sanhal, H. K. Daglar, O. Kara, D. Uygur, and A. Yucel, “Assessment of fetal myocardial performance index in women with pregestational and gestational diabetes mellitus,” The Journal of Obstetrics and Gynaecology Research, vol. 43, pp. 65–72, 2017. View at: Publisher Site | Google Scholar
  77. J. S. Sheffield, E. L. Butler-Koster, B. M. Casey, M. I. DD, and K. J. Leveno, “Maternal diabetes mellitus and infant malformations,” Obstetrics and Gynecology, vol. 100, pp. 925–930, 2002. View at: Google Scholar
  78. J. L. Nold and M. K. Georgieff, “Infants of diabetic mothers,” Pediatric Clinics of North America, vol. 51, pp. 619–637, 2004. View at: Publisher Site | Google Scholar
  79. D. Mitanchez, A. Burguet, and U. Simeoni, “Infants born to mothers with gestational diabetes mellitus: mild neonatal effects, a long-term threat to global health,” The Journal of Pediatrics, vol. 164, pp. 445–450, 2014. View at: Publisher Site | Google Scholar
  80. F. Westermeier, C. Salomón, M. Farías et al., “Insulin requires normal expression and signaling of insulin receptor A to reverse gestational diabetes-reduced adenosine transport in human umbilical vein endothelium,” The FASEB Journal, vol. 29, pp. 37–49, 2015. View at: Publisher Site | Google Scholar
  81. M. Peleli, B. Fredholm, L. Sobrevia, and M. Carlström, “Pharmacological targeting of adenosine receptor signalling,” Molecular Aspects of Medicine, vol. 55, pp. 4–8, 2017. View at: Publisher Site | Google Scholar
  82. E. Guzmán-Gutiérrez, A. Armella, F. Toledo, F. Pardo, A. Leiva, and L. Sobrevia, “Insulin requires A1 adenosine receptors expression to reverse gestational diabetes-increased L-arginine transport in human umbilical vein endothelium,” Purinergic Signal, vol. 12, pp. 175–190, 2016. View at: Publisher Site | Google Scholar
  83. A. Pérez-Pérez, J. L. Maymo, Y. P. Gambino et al., “Activated translation signaling in placenta from pregnant women with gestational diabetes mellitus: possible role of leptin,” Hormone and Metabolic Research, vol. 45, pp. 436–442, 2013a. View at: Publisher Site | Google Scholar
  84. G. Yao, Y. Zhang, D. Wang et al., “GDM-induced macrosomia is reversed by Cav-1 via AMPK-mediated fatty acid transport and GLUT1-mediated glucose transport in placenta,” PLoS One, vol. 12, 2017. View at: Publisher Site | Google Scholar
  85. M. T. Coughlan, K. Oliva, H. M. Georgiou, J. M. Permezel, and G. E. Rice, “Glucose-induced release of tumour necrosis factor-alpha from human placental and adipose tissues in gestational diabetes mellitus,” Diabetic Medicine, vol. 18, pp. 921–927, 2001. View at: Google Scholar
  86. M. T. Coughlan, M. Permezel, H. M. Georgiou, and G. E. Rice, “Repression of oxidant-induced nuclear factor-κB activity mediates placental cytokine responses in gestational diabetes,” The Journal of Clinical Endocrinology and Metabolism, vol. 89, pp. 3585–3594, 2004. View at: Publisher Site | Google Scholar
  87. A. Pérez-Pérez, J. Maymó, Y. Gambino et al., “Insulin enhances leptin expression in human trophoblastic cells,” Biology of Reproduction, vol. 89, p. 20, 2013b. View at: Publisher Site | Google Scholar
  88. J. Martino, S. Sebert, M. T. Segura et al., “Maternal body weight and gestational diabetes differentially influence placental and pregnancy outcomes,” The Journal of Clinical Endocrinology and Metabolism, vol. 101, pp. 59–68, 2016. View at: Google Scholar
  89. R. McManus, K. Summers, B. De Vrijer, N. Cohen, A. Thompson, and I. Giroux, “Maternal, umbilical arterial and umbilical venous 25-hydroxyvitamin D and adipocytokine concentrations in pregnancies with and without gestational diabetes,” Clinical Endocrinology, vol. 80, pp. 635–641, 2014. View at: Publisher Site | Google Scholar
  90. M. Colomiere, M. Permezel, C. Riley, G. Desoye, and M. Lappas, “Defective insulin signaling in placenta from pregnancies complicated by gestational diabetes mellitus,” European Journal of Endocrinology, vol. 160, pp. 567–578, 2009. View at: Publisher Site | Google Scholar
  91. M. Subiabre, L. Silva, R. Villalobos-Labra et al., “Maternal insulin therapy does not restore foetoplacental endothelial dysfunction in gestational diabetes mellitus,” Biochimica et Biophysica Acta Molecular Basis of Disease, 2017. View at: Publisher Site | Google Scholar
  92. S. H. Koning, K. Hoogenberg, K. A. Scheuneman et al., “Neonatal and obstetric outcomes in diet- and insulin-treated women with gestational diabetes mellitus: a retrospective study,” BMC Endocrine Disorders, vol. 16, p. 52, 2016. View at: Publisher Site | Google Scholar
  93. R. T. McGrath, S. J. Glastras, S. Hocking, and G. R. Fulcher, “Use of metformin earlier in pregnancy predicts supplemental insulin therapy in women with gestational diabetes,” Diabetes Research and Clinical Practice, vol. 116, pp. 96–99, 2016. View at: Publisher Site | Google Scholar
  94. B. Persson, M. Stangenberg, U. Hansson, and E. Nordlander, “Gestational diabetes mellitus (GDM). Comparative evaluation of two treatment regimens, diet versus insulin and diet,” Diabetes, vol. 34, pp. 101–105, 1985. View at: Google Scholar
  95. O. Verier-Mine, “Outcomes in women with a history of gestational diabetes. Screening and prevention of type 2 diabetes. Literature review,” Diabetes & Metabolism, vol. 36, pp. 595–616, 2010. View at: Publisher Site | Google Scholar
  96. S. M. Grundy, H. B. Brewer, J. I. Cleeman, S. C. Smith Jr., C. Lenfant, and American Heart Association, National Heart, Lung, and Blood Institute, “Definition of metabolic syndrome: report of the national heart, lung, and blood institute/American Heart Association Conference on Scientific Issues Related to Definition,” Circulation, vol. 109, pp. 433–438, 2004. View at: Publisher Site | Google Scholar
  97. P. M. Catalano, L. Presley, J. Minium, and S. Hauguel-de Mouzon, “Fetuses of obese mothers develop insulin resistance in utero,” Diabetes Care, vol. 32, pp. 1076–1080, 2009. View at: Publisher Site | Google Scholar
  98. L. E. Simental-Mendía, A. Castañeda-Chacón, M. Rodríguez-Morán, and F. Guerrero-Romero, “Birth-weight, insulin levels, and HOMA-IR in newborns at term,” BMC Pediatrics, vol. 12, p. 94, 2012. View at: Publisher Site | Google Scholar
  99. J. Pirkola, A. Pouta, A. Bloigu et al., “Risks of overweight and abdominal obesity at age 16 years associated with prenatal exposures to maternal prepregnancy overweight and gestational diabetes mellitus,” Diabetes Care, vol. 33, pp. 1115–1121, 2010. View at: Publisher Site | Google Scholar
  100. R. Gaillard, E. A. P. Steegers, L. Duijts et al., “Childhood cardiometabolic outcomes of maternal obesity during pregnancy: the generation R study,” Hypertension, vol. 63, pp. 683–691, 2014. View at: Publisher Site | Google Scholar
  101. K. M. Thakali, J. Saben, J. B. Faske et al., “Maternal pregravid obesity changes gene expression profiles toward greater inflammation and reduced insulin sensitivity in umbilical cord,” Pediatric Research, vol. 76, pp. 202–210, 2014. View at: Publisher Site | Google Scholar
  102. J. Saben, F. Lindsey, Y. Zhong et al., “Maternal obesity is associated with a lipotoxic placental environment,” Placenta, vol. 35, pp. 171–177, 2014. View at: Publisher Site | Google Scholar
  103. N. Jansson, F. J. Rosario, F. Gaccioli et al., “Activation of placental mTOR signaling and amino acid transporters in obese women giving birth to large babies,” The Journal of Clinical Endocrinology and Metabolism, vol. 98, pp. 105–113, 2013. View at: Publisher Site | Google Scholar
  104. N. Jansson, A. Nilsfelt, M. Gellerstedt et al., “Maternal hormones linking maternal body mass index and dietary intake to birth weight,” The American Journal of Clinical Nutrition, vol. 87, pp. 1743–1749, 2008. View at: Google Scholar
  105. J. Saben, Y. Zhong, H. Gomez-Acevedo et al., “Early growth response protein-1 mediates lipotoxicity-associated placental inflammation: role in maternal obesity,” The American Journal of Physiology, vol. 305, pp. E1–E14, 2013. View at: Publisher Site | Google Scholar
  106. E. Paré, S. Parry, T. F. McElrath, D. Pucci, A. Newton, and K. H. Lim, “Clinical risk factors for preeclampsia in the 21st century,” Obstetrics and Gynecology, vol. 124, pp. 763–770, 2014. View at: Publisher Site | Google Scholar
  107. T.-H. Hung and T.-T. Hsieh, “Pregestational body mass index, gestational weight gain, and risks for adverse pregnancy outcomes among Taiwanese women: a retrospective cohort study,” Taiwanese Journal of Obstetrics & Gynecology, vol. 55, pp. 575–581, 2016. View at: Publisher Site | Google Scholar
  108. M. Dieber-Rotheneder, S. Beganovic, G. Desoye, U. Lang, and M. Cervar-Zivkovic, “Complex expression changes of the placental endothelin system in early and late onset preeclampsia, fetal growth restriction and gestational diabetes,” Life Sciences, vol. 91, pp. 710–715, 2012. View at: Publisher Site | Google Scholar
  109. W. Xiang, H. Chen, X. Xu, M. Zhang, and R. Jiang, “Expression of endothelial nitric oxide synthase traffic inducer in the placentas of women with pre-eclampsia,” International Journal of Gynaecology and Obstetrics, vol. 89, pp. 103–107, 2005. View at: Publisher Site | Google Scholar
  110. G. D. Ferreira, R. B. Orcy, S. H. Martins-Costa et al., “Insulin stimulation of Akt/PKB phosphorylation in the placenta of preeclampsia patients,” São Paulo Medical Journal, vol. 129, pp. 387–391, 2011. View at: Google Scholar
  111. C. Escudero, P. Bertoglia, M. Hernadez et al., “Impaired A2A adenosine receptor/nitric oxide/VEGF signaling pathway in fetal endothelium during late- and early-onset preeclampsia,” Purinergic Signal, vol. 9, pp. 215–226, 2013. View at: Publisher Site | Google Scholar
  112. X. Wang, N. Athayde, and B. Trudinger, “Maternal plasma from pregnant women with umbilical placental vascular disease does not affect endothelial cell mRNA expression of nitric oxide synthase,” Journal of the Society for Gynecologic Investigation, vol. 11, pp. 149–153, 2004. View at: Publisher Site | Google Scholar
  113. A. Alonso, C. González Del Rey, A. Navarro, J. Tolivia, and C. G. González, “Effects of gestational diabetes mellitus on proteins implicated in insulin signaling in human placenta,” Gynecological Endocrinology, vol. 22, pp. 526–535, 2006. View at: Publisher Site | Google Scholar
  114. L. Sati, B. Soygur, and C. Celik-Ozenci, “Expression of mammalian target of rapamycin and downstream targets in normal and gestational diabetic human term placenta,” Reproductive Sciences, vol. 23, pp. 324–332, 2016. View at: Publisher Site | Google Scholar
  115. H. Chen, H. Chen, Y. Wu, B. Liu, Z. Li, and Z. Wang, “Adiponectin exerts antiproliferative effect on human placenta via modulation of the JNK/c-jun pathway,” International Journal of Clinical and Experimental Pathology, vol. 7, pp. 2894–2904, 2014. View at: Google Scholar
  116. C. Marseille-Tremblay, M. Ethier-Chiasson, J.-C. Forest et al., “Impact of maternal circulating cholesterol and gestational diabetes mellitus on lipid metabolism in human term placenta,” Molecular Reproduction and Development, vol. 75, pp. 1054–1062, 2008. View at: Publisher Site | Google Scholar
  117. M. Subiabre, R. Salsoso, R. Villalobos-Labra et al., “Insulin therapy fails to reverse the human foetoplacental endothelial dysfunction in gestational diabetes mellitus,” Placenta, vol. 51, pp. 117-118, 2017. View at: Google Scholar
  118. C. Salomón, F. Westermeier, C. Puebla et al., “Gestational diabetes reduces adenosine transport in human placental microvascular endothelium, an effect reversed by insulin,” PLoS One, vol. 7, article e40578, 2012. View at: Publisher Site | Google Scholar
  119. K. E. Brett, Z. M. Ferraro, M. Holcik, and K. B. Adamo, “Placenta nutrient transport-related gene expression: the impact of maternal obesity and excessive gestational weight gain,” The Journal of Maternal-Fetal & Neonatal Medicine, vol. 29, pp. 1399–1405, 2016. View at: Publisher Site | Google Scholar

Copyright © 2017 Roberto Villalobos-Labra et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

1281 Views | 446 Downloads | 20 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.